Stephen M. Stahl
YOU?
Author Swipe
View article: Lumateperone as Adjunctive Therapy in Patients With Major Depressive Disorder
Lumateperone as Adjunctive Therapy in Patients With Major Depressive Disorder Open
Trial Registration: ClinicalTrials.gov identifier: NCT04985942.
View article: Should we skip the trip? Clinical implications of psychedelic-associated subjective effects and the potential role of non-hallucinogenic alternatives
Should we skip the trip? Clinical implications of psychedelic-associated subjective effects and the potential role of non-hallucinogenic alternatives Open
The resurgence of interest in classical psychedelics brings both promise and challenges to psychiatric care. Increasing evidence supports the therapeutic potential of psychedelics for a range of mental health conditions, and approval for c…
View article: Management of Parkinson’s disease psychosis: first-line antipsychotic selection and rationale for continuing, combining, or switching
Management of Parkinson’s disease psychosis: first-line antipsychotic selection and rationale for continuing, combining, or switching Open
PDP is a common but still undertreated sequela of PD progression. Pimavanserin is recommended as a first-line antipsychotic therapy based on its established safety and efficacy. While switching strategies are suggested, further study is ne…
View article: Lumateperone for the Treatment of Major Depressive Disorder With Mixed Features or Bipolar Depression With Mixed Features
Lumateperone for the Treatment of Major Depressive Disorder With Mixed Features or Bipolar Depression With Mixed Features Open
Background This randomized, double-blind, placebo-controlled trial (ClinicalTrials.gov identifer NCT04285515) evaluated efficacy and safety of lumateperone to treat major depressive episodes (MDEs) associated with major depressive disorder…
View article: LUMATEPERONE TREATMENT FOR MAJOR DEPRESSIVE EPISODES WITH MIXED FEATURES IN MAJOR DEPRESSIVE DISORDER AND BIPOLAR I OR BIPOLAR II DISORDER
LUMATEPERONE TREATMENT FOR MAJOR DEPRESSIVE EPISODES WITH MIXED FEATURES IN MAJOR DEPRESSIVE DISORDER AND BIPOLAR I OR BIPOLAR II DISORDER Open
Background The DSM-5 and DSM-5-TR define mixed features in major depressive disorder (MDD) or bipolar depression (BPD) as having subsyndromal manic or hypomanic symptoms nearly every day during the majority of days of a major depressive ep…
View article: Demystifying the Antidepressant Mechanism of Action of Stinels, a Novel Class of Neuroplastogens: Positive Allosteric Modulators of the NMDA Receptor
Demystifying the Antidepressant Mechanism of Action of Stinels, a Novel Class of Neuroplastogens: Positive Allosteric Modulators of the NMDA Receptor Open
Plastogens are a class of therapeutics that function by rapidly promoting changes in neuroplasticity. A notable example, ketamine, is receiving great attention due to its combined rapid and long-term antidepressant effects. Ketamine is an …
View article: What is the neurobiology of schizophrenia?
What is the neurobiology of schizophrenia? Open
Schizophrenia spectrum disorders are brain diseases that are developmental dementias (dementia praecox). Their pathology begins in utero with psychosis most commonly becoming evident in adolescence and early adulthood. It is estimated they…
View article: Did Bipolar Disorder Enhance Jackson Pollock’s Ability to Communicate Through Conscious and Unconscious Images (Polloglyphs)?
Did Bipolar Disorder Enhance Jackson Pollock’s Ability to Communicate Through Conscious and Unconscious Images (Polloglyphs)? Open
Experts have been fascinated with Jackson Pollock (born 1912, died 1956) and his famous “drip paintings” ever since he began producing them in the 1940s. It is well documented that Pollock began to have mood swings as a child, with symptom…
View article: Pollock’s Abstract Images in Paintings Prior to His Drip Paintings
Pollock’s Abstract Images in Paintings Prior to His Drip Paintings Open
Although Jackson Pollock is most famous for his drip drawings, these occurred late in his career, starting around 1947. Prior to that he produced some “surrealist inflected” paintings and “gestural abstraction.” Troubled Queen in 1945 is c…
View article: Efficacy and Safety of Esmethadone (REL-1017) in Patients With Major Depressive Disorder and Inadequate Response to Standard Antidepressants
Efficacy and Safety of Esmethadone (REL-1017) in Patients With Major Depressive Disorder and Inadequate Response to Standard Antidepressants Open
Trial Registration: ClinicalTrials.gov identifier: NCT04688164.
View article: Efficacy and Safety of Iloperidone in Bipolar Mania
Efficacy and Safety of Iloperidone in Bipolar Mania Open
Trial Registration: ClinicalTrials.gov identifier: NCT04819776; EudraCT: 2020-000405-83.
View article: Adjunctive agents to antipsychotics in schizophrenia: a systematic umbrella review and recommendations for amino acids, hormonal therapies and anti-inflammatory drugs
Adjunctive agents to antipsychotics in schizophrenia: a systematic umbrella review and recommendations for amino acids, hormonal therapies and anti-inflammatory drugs Open
Question This umbrella review and guidelines aimed to provide evidence to support the rational choice of selected adjunctive therapies for schizophrenia. Study selection and analysis Following the Preferred Reporting Items for Systematic R…
View article: Treatment‐resistant depression: definition, prevalence, detection, management, and investigational interventions
Treatment‐resistant depression: definition, prevalence, detection, management, and investigational interventions Open
Treatment‐resistant depression (TRD) is common and associated with multiple serious public health implications. A consensus definition of TRD with demonstrated predictive utility in terms of clinical decision‐making and health outcomes doe…
View article: Neuropsychiatric Function Improvement in Pediatric Patients with Phenylketonuria
Neuropsychiatric Function Improvement in Pediatric Patients with Phenylketonuria Open
ClinicalTrials.gov, NCT01114737. Registered 27 April 2010, https://clinicaltrials.gov/ct2/show/NCT01114737.
View article: Screening for Bipolar I Disorder and the Rapid Mood Screener
Screening for Bipolar I Disorder and the Rapid Mood Screener Open
Discussion: In our survey, the RMS was favorably evaluated by HCPs. A large percentage of respondents preferred the RMS over the MDQ and indicated that it would likely have a positive impact on clinicians' screening behavior.
View article: The Efficacy of Lumateperone in Patients With Bipolar Depression With Mixed Features
The Efficacy of Lumateperone in Patients With Bipolar Depression With Mixed Features Open
Trial Registration: ClinicalTrials.gov identifier: NCT03249376.
View article: Zuranolone, a Positive Allosteric Modulator of the GABA<sub>A</sub> Receptor: Hypothesized Mechanism of Action in Major Depressive Disorder
Zuranolone, a Positive Allosteric Modulator of the GABA<sub>A</sub> Receptor: Hypothesized Mechanism of Action in Major Depressive Disorder Open
Major depressive disorder (MDD) is a heterogeneous condition characterized by depressed mood and/or loss of interest/pleasure in activities, among other symptoms. Most currently available treatments for depression were developed on the hyp…
View article: Esmethadone-HCl (REL-1017): a promising rapid antidepressant
Esmethadone-HCl (REL-1017): a promising rapid antidepressant Open
This review article presents select recent studies that form the basis for the development of esmethadone into a potential new drug. Esmethadone is a promising member of the pharmacological class of uncompetitive N-methyl-D-aspartate recep…
View article: Rapid onset brain plasticity at novel pharmacologic targets hypothetically drives innovations for rapid onset antidepressant actions
Rapid onset brain plasticity at novel pharmacologic targets hypothetically drives innovations for rapid onset antidepressant actions Open
Numerous new agents with rapid onset antidepressant effects are entering clinical trials and clinical practice. Studies focus on either first-line treatment of major depressive disorder or on patients whose major depressive disorder is res…
View article: Do We Need a New Nomenclature for Atypical Antipsychotics? A Survey of Health Care Professionals and Patients
Do We Need a New Nomenclature for Atypical Antipsychotics? A Survey of Health Care Professionals and Patients Open
Conclusions: Significantly more HCPs and patients had negative reactions to atypical antipsychotic nomenclature compared with mood stabilizer nomenclature for treating bipolar disorder. The broad descriptive atypical antipsychotic class na…
View article: Trazodone once-a-day: A formula for addressing challenges in antidepressant safety and tolerability
Trazodone once-a-day: A formula for addressing challenges in antidepressant safety and tolerability Open
Psychotropic drug properties can vary across different formulations of a compound. Trazodone is a multifunctional drug that exemplifies this phenomenon. Although it is a serotonin reuptake inhibitor, trazodone is a significantly more poten…
View article: Zuranolone, a positive allosteric modulator of the GABAA receptor and a neuroactive steroid: hypothesized mechanism of action in depression
Zuranolone, a positive allosteric modulator of the GABAA receptor and a neuroactive steroid: hypothesized mechanism of action in depression Open
International audience
View article: Muscarinic acetylcholine receptors for psychotic disorders: bench-side to clinic
Muscarinic acetylcholine receptors for psychotic disorders: bench-side to clinic Open
Modern interest in muscarinic acetylcholine receptor (mAChR) activators for schizophrenia began in the 1990s when xanomeline, an M1/M4-preferring mAChR agonist developed for cognitive symptoms of Alzheimer's disease (AD), had unexpected an…
View article: Esmethadone (REL-1017) and Other Uncompetitive NMDAR Channel Blockers May Improve Mood Disorders via Modulation of Synaptic Kinase-Mediated Signaling
Esmethadone (REL-1017) and Other Uncompetitive NMDAR Channel Blockers May Improve Mood Disorders via Modulation of Synaptic Kinase-Mediated Signaling Open
This article presents a mechanism of action hypothesis to explain the rapid antidepressant effects of esmethadone (REL-1017) and other uncompetitive N-methyl-D-aspartate receptor (NMDAR) antagonists and presents a corresponding mechanism o…
View article: Pharmacological Comparative Characterization of REL-1017 (Esmethadone-HCl) and Other NMDAR Channel Blockers in Human Heterodimeric N-Methyl-D-Aspartate Receptors
Pharmacological Comparative Characterization of REL-1017 (Esmethadone-HCl) and Other NMDAR Channel Blockers in Human Heterodimeric N-Methyl-D-Aspartate Receptors Open
Excessive Ca2+ currents via N-methyl-D-aspartate receptors (NMDARs) have been implicated in many disorders. Uncompetitive NMDAR channel blockers are an emerging class of drugs in clinical use for major depressive disorder (MDD) and other n…